Viala Annie, Cornic Françoise, Vacheron Marie-Noëlle
SM 13, Centre Hospitalier Sainte-Anne, 1 Rue Cabanis, 75014 Paris, France.
Schizophr Res Treatment. 2012;2012:368687. doi: 10.1155/2012/368687. Epub 2012 Apr 3.
Although response to treatment for the first episode of schizophrenia is generally favourable, nonadherence with the treatment is the first cause of relapse and rehospitalisation within the next few years. Long-acting injectable antipsychotics (LAIAs) combine the advantages of the newer antipsychotics and the long-acting formulation. The evaluation concerns 25 schizophrenic patients hospitalised for the first time, treated with risperidone long-acting injectable (RLAI) associated with reintegration methods, and followed up for at least 18 months. Clinical observation was completed using Clinical Global Impression (CGI) scale and Global Assessment of Functioning (GAF). Clinical improvement was coupled with a good reintegration rate, very few relapse, or rehospitalisation. Bimonthly injection combined with psychosocial methods improved interactive followup, and therefore patients' compliance with the treatment. Treating with LAIA as early as possible, from the first episode if possible, can reduce relapse, number and duration of rehospitalisation, and cognitive symptoms and improve the quality of life and prognosis.
尽管首次发作的精神分裂症患者对治疗的反应总体良好，但不坚持治疗是未来几年复发和再次住院的首要原因。长效注射用抗精神病药物（LAIA）结合了新型抗精神病药物和长效剂型的优点。本评估涉及25例首次住院的精神分裂症患者，他们接受了利培酮长效注射剂（RLAI）治疗并结合康复方法，随访至少18个月。使用临床总体印象量表（CGI）和功能总体评定量表（GAF）完成临床观察。临床改善与良好的康复率、极少的复发或再次住院相关。每两个月注射一次并结合心理社会方法改善了互动随访，从而提高了患者对治疗的依从性。尽早使用LAIA进行治疗，若可能从首次发作就开始治疗，可减少复发、再次住院的次数和时长、减轻认知症状，并改善生活质量和预后。
